Back to news

Exicure Announces Strategic Expansion into Parkinson’s Disease

Globe Newswire•20/11/2026•13:00 ET
1

Key Highlights

  • ➤Exicure (XCUR) plans acquiring 20%-100% of NeuroQ through common-share issuance
  • ➤X-CUE development phase complete; planned clinical evaluation may take approximately six months
  • ➤Exicure intends providing up to US$500,000 for X-CUE development and commercialization
  • ➤NeuroQ will lead X-CUE development, clinical evaluation, regulatory approval, and commercialization
  • ➤Final acquisition percentage, exchange ratio, and transaction terms remain subject to definitive agreements and approvals

Expert Statements

Jung Soo Kim, Chief Executive Officer of Exicure

“Through this strategic agreement, we are expanding Exicure’s business into innovative medical device technologies designed to address important unmet needs among patients with Parkinson’s disease”

Jung Soo Kim, Chief Executive Officer of Exicure

“With more than a decade of development behind X-CUE and the product ready for planned clinical evaluation, we believe this initiative presents a promising opportunity to advance a differentiated technology toward commercialization and create long-term value for our stockholders.”

WILMINGTON, Del., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 19, 2026, it entered into a Strategic Business Expansion and Investment Agreement with NeuroQ Biologics Inc. (“NeuroQ”) and Laonz Co., Ltd. (“Laonz”) to expand its business into medical device technologies designed to assist patients with Parkinson’s disease.

The agreement focuses on X-CUE, an augmented-reality smart-glasses technology developed over more than a decade to assist patients with Parkinson’s disease who experience freezing of gait, a condition that can significantly affect mobility and daily activities.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in